’Reddit is built for this moment’ - Stock soars on crushed earnings
DURHAM, N.C.—Dale A. Sander, the Chief Financial Officer and Chief Corporate Development Officer of Humacyte, Inc. (NASDAQ:HUMA), recently acquired a significant amount of the company’s common stock. According to a filing submitted to the Securities and Exchange Commission, Sander purchased 20,000 shares on April 10 at a price of $1.53 per share. This transaction amounted to a total value of $30,600. The purchase comes as the stock has shown strong momentum, gaining over 21% in the past week, though InvestingPro analysis suggests the stock is currently overvalued.
Following this acquisition, Sander now holds 40,600 shares indirectly through his spouse, in addition to 2,000 shares owned directly. Humacyte, a company based in Durham, North Carolina, specializes in the development of biological products. With analyst price targets ranging from $3 to $25 and a healthy current ratio of 2.4, the company maintains strong liquidity despite challenging market conditions. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report for deeper analysis of HUMA’s financial health and growth prospects.
In other recent news, Humacyte reported a narrower fourth-quarter loss of $0.16 per share, which was better than analyst projections of a $0.25 per share loss. Despite this, the company generated no revenue for the quarter, consistent with the same period last year. This comes after the FDA approved its vascular graft product, Symvess, in December, and the company commenced its commercial launch by shipping units to two Level 1 trauma centers. CEO Laura Niklason noted that 34 hospitals have begun the approval process to purchase Symvess, with three having completed approvals.
Benchmark analysts maintained a Buy rating with a $17 price target, highlighting Humacyte’s promising pipeline, including plans to file an IND for coronary artery bypass grafting in 2025 and a supplemental BLA for dialysis AV access in 2026. BTIG analyst Ryan Zimmerman also maintained a Buy rating but lowered the price target from $10 to $8, citing the initial commercial traction as evidence of the product’s potential impact. Humacyte ended 2024 with $95.3 million in cash and equivalents and raised an additional $46.6 million through a public stock offering in March 2025. The company’s increased net loss for the full year 2024, amounting to $148.7 million, was primarily due to higher research and development expenses and preparation costs for Symvess’ commercial launch.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.